The EU Concerted Action Workshop on 11q23 Abnormalities in Hematological Malignancies collected 550 patients with abnormalities involving 11q23. Of these, 53 patients had a translocation involving chromosome 11, breakpoint q23, and chromosome 19, breakpoint p13. Karyogram review enabled each patient to be further defined as t(11;19)(q23;p13.1) (21 patients) or t(11;19)(q23;p13.3) (32 patients). There was a marked difference between the type of banding and the translocation identified: t(11;19)(q23;p13.1) was detected predominantly by R-banding, whereas t(11;19)(q23;p13.3) was detected almost solely by G-banding. Additional change was extremely rare in patients with t(11;19)(q23;p13.1) but occurred in nearly half of the patients with t(11;19)(q23;p13.3). Patients with t(11;19)(q23;p13.1) all had leukemia of a myeloid lineage, mostly acute myeloid leukemia (AML), and were predominantly adult. In contrast patients with t(11;19)(q23;p13.3) had malignancies of both myeloid and lymphoid lineage and were mainly infants less than 1 year old. The survival of both groups of patients was generally poor, over 50% of t(11;19)(q23;p13.1) patients died within 2 years of diagnosis and the median survival of acute lymphoblastic leukemia (ALL) patients with t(11;19)(q23;p13.3) was 17.6 months.
Introduction
The translocation t(11;19)(q23;p13) is well documented in the literature with 111 cases cited in the Catalog of Chromosome Aberrations in Cancer. 1 This translocation has been reported in a wide variety of hematological malignancies but the majority have been found in acute lymphoblastic leukemia (ALL) or acute myeloid leukemia (AML) with M4 or M5 FAB type. 1 The breakpoint on chromosome 11 is consistently at band q23. 2 However, the breakpoint on chromosome 19 is variable and can occur at either p13.1 or p13.3. [3] [4] [5] The 19p13.1 breakpoint results in cytogenetically visible 11q+ and 19p− chromosomes. Whereas the 19p13.3 breakpoint forms 11q− and 19p+ chromosomes. Thus both translocations, t(11;19)(q23;p13.1) and t(11;19)(q23;p13.3), are discernible by standard banding analysis. However, due to the morphology of chromosome bands on 19p, each is more likely to be detected by a particular banding technique. The t(11;19)(q23;p13.1) translocation is readily identified by reverse (R) banding but difficult with Giemsa (G) or quinacrine (Q) banding. The converse is true for the t(11;19)(q23;p13.3) translocation. 3 These two translocations involve the same gene, MLL, on 11q23 [6] [7] [8] but different genes on 19p13: ELL at 19p13.1 9, 10 and ENL at 19p13.3.
Recently, a third partner gene for MLL which maps to the same region, 19p13, has been identified and called EEN. This gene was identified in a 22-year-old female patient with AML. Unfortunately her karyotype showed a trisomy 21 with no structural abnormalities so no information about the cytogenetic change can be determined for this novel fusion gene. 14 The t(11;19)(q23;p13.1) translocation has only been observed in patients with myeloid malignancies, occurring mainly in adults over 40 years of age, whereas the t(11;19)(q23;p13.3) translocation has been found in patients with both lymphoid and myeloid malignancies, occurring at a younger age, especially in infants (Ͻ1 year old). 3, 9, 10, 15 We present a series of patients with t (11;19) 
Materials and methods
All 53 patients had been collected through the EU Concerted Action Workshop on 11q23 initiative as described by SeckerWalker. 16 Karyograms of each patient had been reviewed and the translocations, t (11;19) 20 Statistical analyses were performed as described by Secker-Walker. 16 Results t(11;19)(q23;p13.1) -see Table 1 Cytogenetics, FISH, reverse transcriptase polymerase chain reaction (RT-PCR) and Southern blotting:
Full karyotypes for these 21 patients were identified by R banding (18 cases) or G banding analysis (two cases). One of the G banded cases showed the MLL-ELL fusion product by RT-PCR thereby confirming the precise breakpoint on chromosome 19. One patient (142) also had del(17)(p12). Metaphase FISH confirmed t(11;19), using whole chromosome paints (wcp) (four patients) or a series of single copy probes which map to the long arm of chromosome 11 (two patients). A split MLL signal was observed by FISH in five patients. Molecular studies confirmed MLL-ELL fusion by RT-PCR in two patients and rearrangement of MLL by Southern blotting in one of these and in two further patients. Overall, the involvement of the MLL gene was shown in nine patients.
Clinical features:
These 21 patients represented 3.8% (21 of 550) of all 11q23 patients collected and 40% (21 of 53) of patients with t(11;19). Slightly over half the patients were female (12 patients). There were three infants (Ͻ1 year) and one child (1-14 years). The remaining 17 patients were adults (Ͼ14 years), of whom 11 were aged 50 years or more. The white blood cell count (WBC) was available for 20 of 21 patients, median 19 × 10 9 /l and range 1-520 × 10 9 /l.
Morphology and immunophenotyping:
Nineteen of 21 patients with t(11;19)(q23;p13.1) had acute myeloid leukemia (AML) of whom five had therapy-related/secondary (s)AML and 14 had de novo AML. The FAB types of these patients was predominantly M4 or M5 (12 of 18). The two remaining patients had secondary myelodysplastic syndrome (sMDS), one with refractory anemia with excess blasts and the other with chronic myelomonocytic leukemia. Immunophenotypic data was available for 10 of 19 patients with AML (see Table 2 ).
Survival:
Eighteen of the 21 patients received intensive treatment. Two patients received no treatment: patient 562 died on day 1; patient 567, with secondary MDS (sMDS), died 37 days post-diagnosis. Patient 520, with sMDS, received non-intensive/supportive therapy and was alive in chronic phase 7.4 months after diagnosis. Of the treated patients with AML, 15 were known to have achieved complete remission (CR). Overall the prognosis for these patients was poor, 13 of 21 patients had died at the time of analysis, 11 within 2 years of diagnosis. Of the surviving seven patients only three had been followed up for more than 2 years. Three patients received an autologous (128) or allogeneic (279, 468) bone marrow transplant (BMT). All three died within 6 months (279, 468) or 2 years (128) of the BMT. t(11;19)(q23;p13.3) -see Table 3 Cytogenetics, FISH, PCR and Southern blotting:
Karyotypes for these 32 patients with t(11;19)(q23;p13.3) were identified by G banding (29 cases), R banding (one case) or Q banding analysis (two cases). Two patients had complex t(11;19)(q23;p13.3) translocations, and both were diagnosed with pro-B ALL: (1) One patient (618) had a three-way translocation, t(11;18;19)(q23;q22;p13.3) and has been previously published as a case study. 20 FISH, using a MLL probe and wcps to chromosomes 11, 18 and 19, confirmed the translocation and showed that MLL was split between chromosomes 11 and 18. The derivative, der(11)t(11;19) with MLL-ENL fusion was retained as confirmed by RT-PCR. (2) One patient (219) had a complex rearrangement in which the der(11)t(11;19) was involved in a second translocation (see Table 2 ). RT-PCR confirmed MLL-ENL fusion and that the important breakpoint junction 11q23::19p13.3 had been retained. FISH was not performed and therefore the marker chromosome could not be characterized.
The t(11;19) translocation was confirmed by metaphase FISH, using wcps in four patients. The involvement of the MLL gene was confirmed by FISH in seven patients. One additional patient (492) showed only one MLL signal by interphase FISH. Molecular studies confirmed MLL-ENL fusion by RT-PCR in eight patients and rearrangement of MLL by Southern blotting in three patients. Overall the involvement of the MLL gene was confirmed in 16 patients. Seventeen patients had additional numerical and/or structural change. The recurring abnormalities were +X (six patients), +8 (five patients) and an additional copy of the der(19)t(11;19)(q23;p13.3) (two patients).
Clinical features:
These 32 patients represented 5.8% (32 of 550) of all 11q23 patients collected and 60% (32 of 53) of patients with a t(11;19). There were 12 adults, seven children and 13 infants. The white blood cell count was available for 29 patients, median 92 × 10 9 /l, range 1-1000 × 10 9 /l.
Morphology and immunophenotyping:
The majority of patients, 21 of 32 (64%), had acute lymphoblastic leukemia (ALL). The remaining 11 patients had: AML M4 (two patients), M5a (2), M1 (one), M2 (one) and M6 (one), biphenotypic acute leukemia (two) and undefined acute leukemia (two). All patients had de novo acute leukemia. The immunophenotype classification of patients with ALL was predominantly pro-B ALL (CD10−ve, CD19+ve) (11 of 21 patients). The remaining patients had: c-ALL (CD10+ve, CD19+ve, CyIgM-ve) (four patients), pre-B ALL (CyIgM+ve) (three) and T-ALL (CD7+ve) (three). 21 Immunophenotypic data was available for five of seven patients with AML (see Table 2 ).
Survival:
The majority of patients (28 of 32) received intensive treatment. The three untreated patients died on day 3 (95,400) or day 27 (90). Patient 604 received nonintensive/supportive therapy and is still alive at 3.8 months.
No treatment or follow-up information was available for patient 189. Of the 27 treated patients with follow up Ͼ1 month, 24 achieved a CR.
The six intensively treated AML patients achieved a CR. Three had died (3.6, 9.8 and 55.4 months post-diagnosis) and 3 were surviving at 5.4, 10.6 and 106.1 months post-diagnosis. Four patients received a BMT: one patient (64) who was transplanted in second remission, survived nearly 3 more years before dying of leukemia; a second patient (578) is alive over 8.5 years from diagnosis following an autologous BMT; a third patient (117) died shortly after an autologous BMT, and a fourth is surviving 5 months after an allogeneic BMT.
Two patients (90, 95) with ALL died early (days 27 and 3, respectively) without any treatment. The majority of intensively treated patients, 16 of 19, achieved a CR. Of these 16 patients 8 were still in CR between 6 and 85 months (median 23 months) from diagnosis. Six of the remaining patients had relapsed in under 18 months and the remaining two at 18 and 25.7 months, repectively. The median event-free survival was 8.1 months (standard error 9.2 months) with 46.6% event-free survival (standard error 12.1%). Comparison in different age groups (patient 243 excluded) revealed that: (1) failure to achieve a CR was greater in infants (Ͻ1 year old) than in chil- dren and adults (4 of 10 vs 0 of 10); (2) more infants had suffered an event (7 of 10 vs 5 of 10); and (3) more infants had died (7 of 10 vs 2 of 10). The small number of patients precluded statistical analysis. Five patients with ALL had a BMT; all had an autologous BMT and four have since died. The single survivor (342) is currently in his second CR 3 years post-BMT.
Discussion
Fifty-three patients with either t(11;19)(q23;p13.1) or t(11;19)(q23;p13.3) have been described, and these accounted for 9.6% of 11q23 patients collected by the Workshop. There was a marked association between the translocation breakpoints detected and the type of banding used.
Nearly all cases with the 19p13.3 breakpoint were detected using G/Q banding analysis whereas the 19p13.1 breakpoint was virtually always detected using R banding. The difficulty in detecting t(11;19)(q23;p13.1) by G-banded analysis and t(11;19)(q23;p13.3) by R-banded analysis is due to the similarity of the bands distal to 11q23 and 19p13. This marked association between type of banding and the translocation detected, has also been reported by Huret et al, 3 and suggests that detection of both translocations may require both types of banding and that their reported frequencies may be underestimates.
Only one patient with t(11;19)(q23;p13.1) had additional change, and none had a complex or three way translocation. In contrast, half of the patients with t(11;19)(q23;p13.3) had additional change and two patients had complex/three way translocations. Numerical change, mostly single trisomies of chromosome X and/or 8 was the most frequent additional change. The only recurring additional structural change was an additional copy of der(19)t(11;19)(q23;p13.3), present in two patients, the significance of which is discussed in Johansson et al. 22 Additional cytogenetic change, mainly single trisomies especially of chromosome 8, has been reported with both translocations by Huret et al. 3 In this study patients with a t(11;19)(q23;p13.1) all had malignancies involving the myeloid lineage. Most patients had AML and most were cases of M4/M5 FAB type indicating a close association between this translocation and morphology. In contrast, patients with a t(11;19)(q23;p13.3) showed much more heterogeneity; most had ALL, but AML and biphenotypic leukemia also occurred. An association with AML M4/M5 was also seen. The association between t(11;19) and FAB type M4 or M5 is consistent with 11q23 abnormalities as a whole, with 80% of 11q23 patients having a M4/M5 FAB type. 16 Approximately half of the ALL patients with a t(11;19)(q23;p13.3) had a pro-B immunophenotype. The remaining patients were either c-ALL, pre-B ALL or T-ALL, a similar distribution to 11q23 patients as a whole. 16 Overall the morphological distribution of patients between the two types of translocations is consistent with previous reports. 3, 15 Contrary to reports by Huret et al 3 and Felix et al 23 none of the patients with t(11;19)(q23;p13.3) had secondary leukemia, whereas 33% of patients with t(11;19)(q23;p13.1) had secondary leukemia. However, Huret et al 3 described a higher incidence of secondary leukemia for patients with the 19p13.1 breakpoint (20%) than with the 19p13.3 breakpoint (7%).
There were more patients with the distal breakpoint, 19p13.3 (32 patients) than the proximal breakpoint, 19p13.1 (21 patients), a ratio of 1.5:1. A similar cytogenetic study by Huret et al 3 reported a slightly higher ratio of 2.4:1 in favor of the 19p13.3 breakpoint. A cytogenetic and molecular study by Rubnitz et al 15 in childhood acute leukemias reported a ratio of more than 10:1 in favor of the 19p13.3 breakpoint/MLL/ENL fusion transcript.
The survival of patients with hematological malignancy associated with either translocation was generally poor. Over 50% of patients with t(11;19)(q23;p13.1) had died and there were only three patients in continuing CR 2 years from diagnosis. Patients with t(11;19)(q23;p13.3) fared almost as badly, over 40% being dead and over 50% having suffered an event at the time of analysis. These poor survival figures are consistent with those previously reported. 3 However, there is evidence that a subset of patients with t(11;19)(q23;p13.3) may have a good prognosis. Eight patients were in first remission more than 2 years from diagnosis. Six of these patients had ALL, six were aged between 10 and 20 and five were male.
Three patients had T-ALL were aged 15-19 and were in first remission 6 months, 4 years and 4.5 years post-diagnosis. A good survival rate has been observed before for older children with T-ALL and t(11;19)(q23;p13.3). Huret et al 3 reported four T-ALL patients, aged 7-13 years, in first remission for between 3.5 and 11 years. The apparently good survival of these patients with an 11q23 abnormality remains a paradox.
